2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-119092
    Bisaramil 89194-77-4 98%
    Bisaramil is an orally active antiarrhythmic agent. Bisaramil exerts concentration dependent inhibitory effect on PMA-stimulated free radical generation and prolonged the time lag concentration dependently.
    Bisaramil
  • HY-119306
    MCC-134 181238-67-5 98%
    MCC-134, a blocker of mitochondrial and opener of surface ATP-sensitive K+ (KATP) channels, abrogates cardioprotective effects of chronic hypoxia. MCC-134 is a vasorelaxing agent.
    MCC-134
  • HY-119379
    Fonsartan free acid 144628-52-4 98%
    Fonsartan (HOE-720) free acid is an orally active angiotensin II receptor (AT1R) antagonist with an IC50 value of 0.48 nM, exhibiting potent antihypertensive activity. Fonsartan free acid dose-dependently inhibits angiotensin II-induced pressor response in rats (ID50 = 0.11 mg/kg) and shows significant long-lasting blood pressure-lowering effects in high-renin animal models. Fonsartan free acid is primarily used in research on hypertension and cardiovascular diseases.
    Fonsartan free acid
  • HY-119544
    Ripisartan 148504-51-2 98%
    Ripisartan (UP-2696) is an angiotensin II receptor antagonist. Ripisartan is orally available. Ripisartan binds to angiotensin II receptors, dilates blood vessels, and lowers blood pressure.
    Ripisartan
  • HY-119545
    PD159790 179598-53-9 98%
    PD159790 is a selective endothelin-converting enzyme-1 (ECE-1) inhibitor, with an EC50 of 28.1 μM.
    PD159790
  • HY-119557
    Buthiazide 2043-38-1 98%
    Buthiazide (Butizide) is a diuretic compound that can be used for high blood pressure research.
    Buthiazide
  • HY-119667
    Enrasentan 167256-08-8 98%
    Enrasentan (SB 217242) is an endothelin (ET) receptor antagonist. Enrasentan has antihypertensive effects.
    Enrasentan
  • HY-119735
    Curcolone 17015-43-9 98%
    Curcolone is a sesquiterpenoid that inhibits collagen-induced or arachidonic acid (AA)-induced platelet aggregation.
    Curcolone
  • HY-119762
    Spizofurone 72492-12-7 98%
    Spizofurone is an anti-ulcer compound with increased gastric mucosal blood flow activity and oral activity. Spizofurone has a similar mechanism of action to PGE2 (HY-101952), Spizofurone is capable of acting through local and systemic pathways and may promote ulcer healing by improving blood supply to the gastric mucosa. Spizofurone can be used to study the development strategy of gastric ulcer.
    Spizofurone
  • HY-119817
    Flosequinan 76568-02-0 98%
    Flosequinan is a balanced vasodilator. Flosequinan not only significantly reduces systemic vascular resistance, but also significantly reduces the beating component of left ventricular afterload, characteristic impedance and arterial wave reflection, which can be used in the research of acute heart failure.
    Flosequinan
  • HY-119844
    Anidoxime 34297-34-2 98%
    Anidoxime is an oral activity analgesic agent.
    Anidoxime
  • HY-119860
    Ataprost 83997-19-7 98%
    Ataprost (ONO 41483) is an orally active Carboprostacyclin (HY-112322) analogue. Ataprost exhibits 2.6 times more active than Carboprostacyclin in inhibiting ADP-induced platelet aggregation in vitro. Ataprost has the ability to relieve coronary spasm.
    Ataprost
  • HY-119873
    Celiprolol 56980-93-9 98%
    Celiprolol (REV 5320) is a potent, cardioselective and orally active β1-andrenoceptor r antagonist with partial β2 agonist activity, with Ki values of 0.14-8.3 μM. Celiprolol has antihypertensive and antianginal activity, and can be used for the research of cardiovascular disease such as high blood pressure.
    Celiprolol
  • HY-119890
    Isbogrel 89667-40-3 98%
    Isbogrel (CV-4151) is a potent selective inhibitor of thromboxane A2 synthase. Isbogrel has oral activity and inhibits blood TXA2 generation with an ID50 value of 0.04 mg/kg.
    Isbogrel
  • HY-119902
    Bistrifluron 201593-84-2 99.38%
    Bistrifluron has insecticidal effects on the larval stage, and also has an effect on adult longevity, reproduction, and hatchability. Bistrifluron is used for the control of a variety of Lepidopterous pests.
    Bistrifluron
  • HY-119926
    13-Hydroxylupanine 15358-48-2 98%
    13-Hydroxylupanine (Hydroxylupanine) is the typical alkaloid profile of sweet lupins.13-Hydroxylupanine blocks ganglionic transmission, decreases cardiac contractility and contracts uterine smooth muscle.
    13-Hydroxylupanine
  • HY-119961
    (+)-Mepivacaine 24358-84-7 99.72%
    (+)-Mepivacaine is a racemic isomer of Mepivacaine (HY-B0517), which has analgesic and vasoconstrictive activity. Mepivacaine is an amide type agent that temporarily causes local loss of consciousness. Mepivacaine binds to specific voltage-gated sodium channels on neuronal cell membranes, inhibiting sodium influx and membrane depolarization.
    (+)-Mepivacaine
  • HY-119995
    Chloropyramine 59-32-5 98%
    Chloropyramine is competitive reversible H1 receptor antagonist. Chloropyramine also has anti-tumour activity in breast cancer. Chloropyramine can be used for the research of allergic conditions, such as conjunctivitis and bronchial asthma.
    Chloropyramine
  • HY-120147
    Ethiazide 1824-58-4 98%
    Ethiazide is a thiazole diuretic which inhibits renal reabsorption of sodium and water, thereby increasing urine excretion, reducing fluid retention, and lowering blood volume and blood pressure. Ethiazide can be used for cardiovascular research.
    Ethiazide
  • HY-120200
    YF-452 1951466-83-3 98%
    YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic agent candidate for cancer research.
    YF-452
Cat. No. Product Name / Synonyms Application Reactivity